London-listed Poolbeg Pharma “is entering a very exciting” phase, its chief executive said on Monday, after the company received human trial approval for its influenza drug in the UK in
Poolbeg Pharma (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss interim results for the six months to 30th June 2022. Jeremy talks us through the financial and operational highlights, the
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, today announced its unaudited interim results for the six months to 30 June 2022.
AI Magazine explores the importance of artificial intelligence (AI) as the healthcare industry continues to digitise and utilise tech for drug discovery Recently MarketsandMarkets released an exclusive report on artificial intelligence
Last month, Alphabet’s artificial intelligence subsidiary, DeepMind, stunned the world of science by presenting something truly spectacular: a snapshot of nearly every existing protein on Earth — 200 million of
Influenza is a highly contagious respiratory illness caused by influenza virus. There are two main types of human influenza viruses: A and B. There are also many sub-types and strains.
Poolbeg Pharma has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to
Poolbeg Pharma has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to
Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
